BioControl Medical has announced that the pilot clinical study of its CardioFit vagus nerve stimulation system has been recognized as seminal original research in the European Journal of Heart Failure. According to a recent editorial, “the highly cited open-label Phase II study [of the CardioFit] by De Ferrari et al. demonstrated for the first time that chronic vagus nerve stimulation is associated with improvements in New York Heart Association (NYHA) class.”
